EUCTR2005-000965-21-DK进行中（未招募）不适用
A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulations of GlaxoSmithKline (GSK) Biologicals’ new generations meningococcal serogroups A, C, W-135, Y-tetanus toxoid conjugate (MenACWY-TT) vaccine versus one subcutaneous dose of MENCEVAX™ ACWY in healthy adolescents/young adults aged 15-19 years - MenACWY-TT-012
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects who the investigator believes they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •- A male or female between, and including, 15 and 19 years of age at the time of the first vaccination.
- •- Written informed consent obtained from the subject prior to enrolment (for subjects below the legal age of consent, written informed consent must be obtained from a parent or legally acceptable representative and, in addition, the subject should sign and personally date a written informed assent).
- •- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •- Previously completed routine childhood vaccinations to the best of his/her knowledge and/or his/her parents/legally acceptable representative’s knowledge.
- •- If the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or DepoProvera®) for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after the vaccination
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during thestudy period. (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •- Any chronic drug therapy to be continued during the study period.
- •- Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the study vaccine dose.
- •- Previous vaccination against meningococcal disease of serogroup A, C, W-135 or Y.
- •- Previous vaccination against tetanus within the last 6 months.
- •- History of meningococcal disease.
- •- Known exposure to N. meningitidis of serogroup A, C, W-135 or Y within previous 12 months.
- •- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •- A family history of congenital or hereditary immunodeficiency.
- •- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •- Major congenital defects or serious chronic illness.
- •- History of any neurologic disorders or seizures.
- •- Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., Axillary temperature <37.5°C / Oral temperature <37.5°C).
- •- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- •- Pregnant or lactating female.
- •- Female planning to become pregnant or planning to discontinue contraceptive precautions.
研究者
相似试验
进行中（未招募）
1 期
A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulations of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroups A, C, W-135, Y-tetanus toxoid conjugate (MenACWY-TT) vaccine versus one subcutaneous dose of MENCEVAX™ ACWY in healthy adolescents/young adults aged 15-19 years - MenACWY-TT-009Primary immunization of healthy adolescents/young adults against meningococcal disease due to Neisseria meningitidis (N. meningitidis) of serogroups A, C, W-135 and YEUCTR2004-004248-37-BEGlaxoSmithKline Biologicals
进行中（未招募）
不适用
A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine versus MenC-CRM197 conjugate vaccine or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old. - MenACWY-TT-010, 011 BST:010Primary immunization of healthy children aged 12-14 months and 3-5 years against meningococcal serogroups A, C, W-135 and Y diseases.EUCTR2004-003768-32-ATGlaxoSmithKline Biologicals500
进行中（未招募）
不适用
A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Biologicals’ new generations meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old. - MenACWY-TT-013, 014 BST:013EUCTR2005-001288-73-DEGlaxoSmithKline Biologicals500
进行中（未招募）
不适用
A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Biologicals’ new generations meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old. - MenACWY-TT-013, 014 BST:013Primary immunization of healthy children aged 12-14 months and 3-5 years against meningococcal serogroups A, C, W-135 and Y diseases.EUCTR2005-001288-73-ATGlaxoSmithKline Biologicals500
进行中（未招募）
不适用
A phase II, randomized, partially double blind, controlled study to evaluate the immunogenicity, safety, and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis (RA) who have relapsed despite use of an anti-TNFa biological drug, due to anti-drug antibodiesMedDRA version: 12.0Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2009-012041-35-FReovacs SA48